TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Venous thromboemboli (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Adverse events after single dose
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of ropeginterferon alfa-2b after single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression profile of the epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful phone call contact at 30 days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Timed Up Go (TUG) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sadness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hand-grip strength test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of cortical bone window based on CT scan evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vancomycin concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of BFI-Bowel Function Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of BPI-SF
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Major Adverse Events (MACE) Occurrence Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in Forced Expired Volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of puffs/day of rescue medication (Salbutamol)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity of GUSS-ICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of GUSS-ICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque location and activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of > 50% coronary stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensibility, specificity, positive and negative predictive values of MSCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC(0-24) of TAK-536
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of TAK-536
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1/2 of TAK-536
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progression to severe COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: need for ICU or death
Endpoint domain: Mortality/survival
Primary endpoint: grade 3 or grade 4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Use of calcium/calcitriol at 1 year post-transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in lumbar disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Depletion of CSF B-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measurement of nitric oxide and eNOS in placental tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of superoxide in maternal serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UCL injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Posttest Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Posttest Happiness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Posttest Life Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: C1-inhibitor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cure of C. difficile infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Protection against malaria infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Successful delivery of spinal anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to cellulitis resolving
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: smooth muscle surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progressive slowing of Visual Field deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical outcomes after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptom free days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in asthma related school absence ratio
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient symptom burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cancer survival
Endpoint domain: Mortality/survival
Primary endpoint: Drug-cue induced craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days to relapse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diplopia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical response of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Standardized Uptake Values (SUV) in Focal Anatomical Regions of the Heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean SUV of Whole Heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endogenous analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of caregivers logging onto the BMT Roadmap
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Log-transformed Urinary Albumin-to-creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum tolerated dose of TPI 287
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % CD63 expression on basophil membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Parental involvement
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Disease care behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: venous thromboembolic event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Relative bioavailability of AZD9056
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-PRP antibody concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urinary Hippuric Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary PAGN Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Nitrogen as a Conjugate of the Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Stand-Walk-Sit Test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade 3 or Grade 4 Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Time to resolution of clinical signs of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fate of the dominant follicle or luteal structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Influenza Vaccine Seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in mean systolic ABPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Eating disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive and Negative Percent Agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marijuana relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of meglumine antimoniate treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in PaCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinician's Global Aesthetic Improvement Assessment (CGAIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response defined using the Choi criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity events (regimen-related death, transaminitis, infection, leukopenia grade 3 or higher)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to obtain maximum sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The highest level of sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The degree of maximum motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discriminatory value of MRI perfusion curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discriminatory value of MRI ADC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discriminatory value of MRI D-value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progesterone rise above 1.5 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in individual weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GI discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sustained Virologic Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Grade 1 Upper GI and/or 2-4 Lower GI aGVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Onset of action measured by change in Total Nasal Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in proliferative index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in asthma control test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Beck Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in Beck Depression Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Subjects That Experienced Rupture or Aneurysm Related Death
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of bone marrow blasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Expression of Survivin protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Expression of p53
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes of serum vascular endothelial growth factor (VEGF) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Net Iron Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Facial Action Summary Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Fibroblast Growth Factor 23 (FGF-23)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical Type Cataractogenic Potential Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Nuclear Opalescence Type Cataractogenic Potential Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Posterior Subcapsular Type Cataractogenic Potential Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Number of patients with Lymphoma response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Concentration of Adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of Leptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of TNF-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Successfully Completed the 1-year Intervention
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients partaking in recommended physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants With LMB-100 Plasma Drug Levels Above Threshold 600ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Serious Adverse Events Related to LMB-100
Endpoint domain: Adverse events/effects
Primary endpoint: Neuropsychiatric Inventory Nursing Home Version
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Local carcinoma recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Composite rates of ordering potentially low-value services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum Tolerated Dose (MTD) of MC2 TCR T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective anti-tumor responses of MC2 TCR T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of dysmenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of myocardial denervation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vaginal swab test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of gingival recession depth (GR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of probing pocket depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological assessment for radiolucent areas and osteolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance characteristics of RAC for diagnosing H. pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of Linear Dysphotopsia
Endpoint domain: Adverse events/effects
Primary endpoint: Biochemical control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total Postsurgical Morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in macular pigment optical density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Insulin Net Incremental Area-Under-The-Curve (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Apnea/bradycardia events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of colics symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reversal of Worsening Renal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of participants with serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of employees tested with evidence of SARS-CoV-2 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Likelihood of clinically relevant infection with SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to recovery of the train-of-four (TOF) ratio to 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount-depth of muscle overlying the carpal tunnel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Levels of N-acetylaspartate (NAA) in the cervical spinal cord
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Normalized rate in serum ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Normalization and/or Improvement of Metabolic Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Count of Participants With Serious and Non-serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Vaginal bleeding events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axial length in eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength muscle evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasite Clearance Half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of progression of clinical measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of progression of biochemical measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non invasive blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse oxymeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of genetic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV antibody detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VEGF-A levels at D1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive fluid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genotype frequency of CYP1A2 polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genotype frequency of GSTP polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genotype frequency of PGC1a polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve from Hour 0 to Hour 8 (AUC8) for BIIB074
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) for BIIB074
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Elimination Half-Life (t1/2) of BIIB074
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants requiring additional pharmacological uterotonic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: EC50 of remifentanil for preventing persistent cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EC50 of remifentanil for preventing defensive movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma amino acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Degree of caregiving burden on caregivers (BIC-11)
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Percent change from baseline in serum uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Steady state oxipurniol area under the serum concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to All-Cause Discontinuation of Study Drug
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Immunological phenotyping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Angle A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type and number of services developed for professionals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serum neurofilaments light chain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Survival at 2 Years
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients free of disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: LH Peak in Response to Estrogen Positive Feedback
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes